Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![PrismMarketView Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1257318598386696195.png) PRISM MarketView [@PrismMarketView](/creator/twitter/PrismMarketView) on x 4668 followers
Created: 2025-07-07 14:04:33 UTC

Apogee Therapeutics $APGE shares surged pre-market after its eczema drug APG777 delivered best-in-class results in a Phase X trial. The IL-13 antibody hit all endpoints and could challenge Dupixent, co-developed by @sanofi ( $SNY) and @Regeneron ( $REGN), with less frequent dosing.



XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1942223213108269549/c:line.svg)

**Related Topics**
[$regn](/topic/$regn)
[$sny](/topic/$sny)
[stocks](/topic/stocks)
[$apge](/topic/$apge)
[sanofi](/topic/sanofi)
[stocks healthcare](/topic/stocks-healthcare)
[regeneron pharmaceuticals inc](/topic/regeneron-pharmaceuticals-inc)

[Post Link](https://x.com/PrismMarketView/status/1942223213108269549)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

PrismMarketView Avatar PRISM MarketView @PrismMarketView on x 4668 followers Created: 2025-07-07 14:04:33 UTC

Apogee Therapeutics $APGE shares surged pre-market after its eczema drug APG777 delivered best-in-class results in a Phase X trial. The IL-13 antibody hit all endpoints and could challenge Dupixent, co-developed by @sanofi ( $SNY) and @Regeneron ( $REGN), with less frequent dosing.

XXX engagements

Engagements Line Chart

Related Topics $regn $sny stocks $apge sanofi stocks healthcare regeneron pharmaceuticals inc

Post Link

post/tweet::1942223213108269549
/post/tweet::1942223213108269549